Collaborate with IAMI

The Institute for Advanced Medical Isotopes (IAMI) is a full-spectrum radiopharmaceutical development facility for research into medical isotopes and radiopharmaceuticals. 

Located on-site at TRIUMF, this 2500 m² facility includes a dedicated TR-24 cyclotron and state-of-the-art radiopharmaceutical development laboratories, including including cGMP-capable facilities. The IAMI team provides commercial and industry partners with industry-leading expertise, oversight, and support for partner-led isotope research and applications.

Learn more about our options for collaborating with IAMI:

With a dedicated TR-24 cyclotron, IAMI offers access to a wide variety of established and emerging radioisotopes for research and development, including: 

• ¹¹C PET
• ¹⁸F PET
• ⁴⁴Sc PET
• ⁴⁵Ti PET
• ^52,54Mn PET
• ⁵⁸Co Auger therapy
• ⁶⁴Cu PET/ ⁶⁷Cu β^– therapy
• ⁶⁸Ga PET
• ⁸⁶Y PET
• ⁸⁹Zr PET
• ^99mTc SPECT/ ^94mTc PET
• ¹⁰³Pd Auger therapy
• ¹¹⁹Sb Auger/¹¹⁸Sb PET/¹¹⁷Sb SPECT
• ^132/135La PET / Auger
• ^149,155,161Tb / alpha / SPECT / β^– therapy
• ¹⁶⁵Er Auger therapy
• ¹⁹⁷Hg Auger therapy
• ²⁰³Pb/ ²¹²Pb SPECT / alpha therapy
• ^223,224Ra alpha therapy
• ²²⁵Ac/²¹³Bi alpha therapy
• ²³⁰U/²²⁶Th alpha therapy

IAMI is located on the south-east corner of the TRIUMF site.

Available are: 

• Six hotlabs (cGMP-compatible)
• Quality control laboratory space

IAMI also has a centralized control room and integrated shipping and receiving facilities. 

IAMI offers certified, full spectrum radiopharmaceutical development support for private and academic partners, including:

• Radiopharmaceutical research capacity 
• Manufacturing and process development (including e.g., for regulatory requirements)
• Dedicated medical isotope production
• Separation and labelling of radiopharmaceuticals
• Preparation of clinically-suitable injectable doses

IAMI positions its partners for leadership in next-generation diagnostics and targeted therapies.

The facility accelerates the transfer of radioisotope and radiopharmaceutical innovation into clinically-relevant products, while safeguarding IP rights and enabling preferred access for collaborators. 

Working with TRIUMF’s in-house commercialization and innovation team, IAMI enables co-development of agreements to generate shared intellectual property, paired with commercialization pathways and regulatory support.

Contact us for more information. 

Interested in collaborating with IAMI?

Contact the IAMI team with any inquiries related to:

• Facility configuration and access
• Prospective partnership, IP, or service agreements
• Schedules and availability
• Any other opportunities or questions

General inquiries: communications@triumf.ca